Pharma, Other Stakeholders Urge Lawmakers To Further Tweak Drug Price Negotiation

By Gabrielle Wanneh / September 23, 2025 at 4:09 PM

On the heels of Congress expanding the orphan drug exclusion in the Medicare drug price negotiation program, a coalition of drug companies, insurers and patient advocacy groups have stepped up efforts to convince lawmakers to pass legislation that would stretch out the timeline for when small-molecule drugs are eligible for price negotiation.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.